Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
Hideki Iwamoto, Tomotake Shirono(Kurume University), Masahito Nakano(Kurume University), Hironori Koga(Kurume University), Takuji Torimura(Omuta hospital), Naoki Kamachi(Kurume University), Miwa Sakai(Kurume University), Shigeo Shimose(Kurume University), Akira Kajiwara(Kurume University), Masatoshi Tanaka(Fukushima Medical University), Ryoko Kuromatsu(Kurume University), Takashi Niizeki(Kurume University), Hiroyuki Suzuki(Kurume University), Taizo Yamaguchi, Satoshi Itano(Kurume University Hospital), Yu Noda(Kurume University), Shusuke Okamura(Kurume University)
Cited by 59
Related Papers
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
|Journal of Hepatology|1997|614
Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
|Hepatology Research|2019|539
Aerobic vs. resistance exercise in non-alcoholic fatty liver disease: A systematic review
|Journal of Hepatology|2016|504
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
|Liver International|2020|410